Department of Community Medicine, Faculty of Medicine, Chiang Mai University, Thailand.
Center of Biomolecular Therapy and Diagnostic, Faculty of Associated Medical Sciences, Chiang Mai University, Thailand; Center of Innovative Immunodiagnostic Development, Faculty of Associated Medical Sciences, Chiang Mai University, Thailand.
Vaccine. 2022 May 9;40(21):2915-2924. doi: 10.1016/j.vaccine.2022.04.020. Epub 2022 Apr 13.
CoronaVac was administered as the primary COVID-19 vaccine for Thai health care workers (HCWs) in early 2021 in response to the epidemic of new variants. This study aimed to evaluate the dynamic of humoral immune response as well as the short-term side effects resulting from the booster dose of BNT162b2 following completion of a CoronaVac double-dose in Thai HCWs.
This study was conducted at a teaching hospital in Northern Thailand during August and September 2021. The participants were 50 HCWs who were vaccinated with 2 doses of CoronaVac and were scheduled to receive a booster dose of BNT162b2. Anti-SARS-CoV-2 IgG antibodies levels and short-term side effects were assessed. The anti-RBD level was determined using Architect SARS-CoV-2 IgG II Quant (Abbott).
Of the 50 participants, 37 were female. The median age was 33.0 years old. The average time between the second CoronaVac shot and the BNT162b2 booster shot was 81.7 days (SD = 25.0). The median anti-SARS-CoV-2 IgG antibody level on booster vaccination date, as well as day 14, and day 28 after the booster were 335.5 AU/ml, 31,613.5 AU/ml, and 20,311.9 AU/ml, respectively. Fourteen days after the booster, 94% of participants had anti-SARS-CoV-2 IgG antibody levels higher than 50.0 AU/ml. Being female, higher log anti-SARS-CoV-2 IgG antibodies prior to booster vaccination, and longer interval between the second shot and the booster shot were found to be significantly associated with higher levels of anti-SARS-CoV-2 IgG antibodies at both day 14 and day 28 after the booster. There were no reports of serious adverse events.
A booster dose of BNT162B2 promoted a high level of anti-SARS-CoV-2 IgG antibodies among HCWs who received 2 doses of CoronaVac. The time between the second CoronaVac shot and the booster shot should be at least three months. There were no severe adverse effects observed.
为应对新型变异病毒，2021 年初，科罗娜疫苗被用作泰国医护人员（HCW）的主要 COVID-19 疫苗。本研究旨在评估在完成两剂科罗娜疫苗接种后，接种 BNT162b2 加强针后体液免疫反应的动态变化，以及泰国 HCW 中接种 BNT162b2 加强针后的短期副作用。
本研究于 2021 年 8 月至 9 月在泰国北部的一家教学医院进行。研究对象为 50 名接种 2 剂科罗娜疫苗并计划接种 BNT162b2 加强针的 HCW。评估抗 SARS-CoV-2 IgG 抗体水平和短期副作用。使用 Architect SARS-CoV-2 IgG II Quant（雅培）测定抗 RBD 水平。
50 名参与者中，37 名为女性。中位年龄为 33.0 岁。第二剂科罗娜疫苗和 BNT162b2 加强针之间的平均时间为 81.7 天（SD=25.0）。加强针接种日、第 14 天和第 28 天的抗 SARS-CoV-2 IgG 抗体中位数分别为 335.5 AU/ml、31613.5 AU/ml 和 20311.9 AU/ml。加强针接种后 14 天，94%的参与者的抗 SARS-CoV-2 IgG 抗体水平高于 50.0 AU/ml。女性、加强针接种前更高的抗 SARS-CoV-2 IgG 抗体水平和第二针与加强针之间更长的间隔与加强针接种后第 14 天和第 28 天更高的抗 SARS-CoV-2 IgG 抗体水平显著相关。没有报告严重不良事件。
接种 BNT162B2 加强针可提高接种 2 剂科罗娜疫苗的 HCW 对 SARS-CoV-2 IgG 抗体的高水平。第二剂科罗娜疫苗和加强针之间的时间间隔应至少为三个月。没有观察到严重的不良反应。
